SDGR Schrodinger Inc.

68.43
+2.03  (+3%)
Previous Close 66.4
Open 65.95
52 Week Low 46.27
52 Week High 117
Market Cap $4,824,666,046
Shares 70,505,130
Float 44,917,620
Enterprise Value $4,133,000,146
Volume 436,389
Av. Daily Volume 575,148
Stock charts supplied by TradingView

Latest News

  1. NEW YORK and SHANGHAI and SAN FRANCISCO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, and Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))), an innovative commercial-stage biopharmaceutical company, today announced a global discovery, development and commercialization collaboration focused on a novel program in oncology targeting DNA damage response.

    "With an established track record of developing and commercializing therapeutics in oncology, Zai Lab is an ideal partner for Schrödinger on this project," said Karen Akinsanya, Ph.D., executive vice president, chief biomedical scientist and head of discovery R&D at Schrödinger…

    NEW YORK and SHANGHAI and SAN FRANCISCO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, and Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))), an innovative commercial-stage biopharmaceutical company, today announced a global discovery, development and commercialization collaboration focused on a novel program in oncology targeting DNA damage response.

    "With an established track record of developing and commercializing therapeutics in oncology, Zai Lab is an ideal partner for Schrödinger on this project," said Karen Akinsanya, Ph.D., executive vice president, chief biomedical scientist and head of discovery R&D at Schrödinger. "Together, we will aim to accelerate and expand our focus on targeted DNA damage response inhibition, which is emerging as an important therapeutic strategy for a broad range of cancers. Additionally, the structure of this collaboration provides us with the opportunity to gain development and commercial expertise and the potential to participate more significantly in the downstream value of the program."

    "We are pleased to be collaborating with Schrödinger, a recognized leader in physics-based computational drug discovery," said Alan Sandler, M.D., president and head of global development, oncology, at Zai Lab. "This program will complement our existing discovery efforts in the DNA damage response pathway in addition to potential combinatorial approaches within our pipeline, such as with the PARP inhibitor Zejula."

    The research program will be conducted jointly by the Schrödinger and Zai Lab scientific teams. The companies will be responsible for their own research program expenses, and under the terms of the collaboration agreement, Zai Lab will make an upfront payment to Schrödinger to help fund Schrödinger's share of research costs. Following the selection of a development candidate, Zai Lab will assume primary responsibility for global development, manufacturing and commercialization. The agreement provides Schrödinger co-development and co-commercialization rights in the U.S. If Schrödinger elects to co-fund clinical development of a product candidate under the collaboration, it will be entitled to 50 percent of the profits, if any, from the commercialization of such product candidate in the United States. Schrödinger will also be eligible to receive up to approximately $338 million in preclinical, clinical, regulatory and sales-based milestone payments. Additionally, Schrödinger is entitled to receive royalties on net sales outside the U.S.

    About Schrödinger

    Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger's multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

    Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

    About Zai Lab

    Zai Lab (NASDAQ:ZLAB, HKEX: 9688))) is an innovative commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer and infectious and autoimmune diseases to patients in China and around the world. We aim to address significant unmet medical needs in large, fast-growing segments of the pharmaceutical market. Our experienced team has secured partnerships with leading global biopharmaceutical companies to generate a broad pipeline of potentially innovative, marketed products and product candidates. We have also built an in-house team with strong drug discovery and translational research capabilities and are establishing a pipeline of proprietary drug candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to positively impact human health worldwide.

    For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

    Schrödinger Forward Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those regarding our expectations about the speed and capacity of our computational platform, our ability to discover novel therapeutics under the collaboration with Zai Lab, the potential of our collaboration with Zai Lab to develop new therapies, our ability to realize potential milestones, royalties or other payments under the collaboration and the risk that we may not realize the expected benefits of the collaboration. Statements including words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including our reliance upon third-party providers of cloud-based infrastructure to host our software solutions, our reliance on third party contract research organizations to assist in the discovery of development candidates, our reliance on Zai Lab to perform its obligations to develop and commercialize any development candidates discovered by us under the collaboration, the uncertainties inherent in drug development and commercialization, uncertainties associated with the regulatory review of clinical trials and applications for marketing approvals, the potential impact of the COVID-19 pandemic on our operations or the operations of third parties we rely on, as well as the other risks and uncertainties identified under the caption "Risk Factors" and elsewhere in our Securities and Exchange Commission filings and reports, including the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 5, 2021, as well as future filings and reports by us. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, we undertake no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.

    Zai Lab Forward-Looking Statements

    This press release contains statements about future expectations, plans and prospects for Zai Lab, including, without limitation, statements regarding the plans and potential benefits of the global drug discovery, co-development and co-commercialization collaboration in oncology. These statements may contain words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would" and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from its approved products; (2) our ability to finance its operations and business initiatives and obtain funding for such activities, (3) the results of clinical and pre-clinical development of its product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) the effects of the novel coronavirus (COVID-19) pandemic on our business and general economic, regulatory and political conditions and (6) the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. We anticipate that subsequent events and developments will cause our expectations and assumptions to change and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    Schrödinger Contacts

    Jaren Irene Madden (Investors)

    Schrödinger, Inc.



    617-286-6264

    Tracy Lessor (Media)

    Schrödinger, Inc.



    617-519-9827

    Kit Rodophele

    Ten Bridge Communications



    617-999-9620

    Zai Lab Contacts

    Billy Cho, CFO

    +86 137 6151 2501

    Media: Ryo Imai / Robert Flamm, Ph.D.

    Burns McClellan, on behalf of Zai Lab

    212-213-0006 ext. 315 / 364

    /

    Investors: Mike Zanoni

    Endurance Advisors, on behalf of Zai Lab

    610-442-8570

    Source: Zai Lab Limited



    Primary Logo

    View Full Article Hide Full Article
  2. Schrödinger (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a conference call and webcast on Thursday, August 12, 2021, at 8:30 a.m. ET to discuss second quarter 2021 financial results and provide a general business update.

    The live webcast can be accessed under "News & Events" in the investors section of Schrödinger's website, https://ir.schrodinger.com/news-and-events/event-calendar. To participate in the live call, please dial (833) 727-9520 (domestic) or +1 (830) 213-7697 (international) and refer to conference ID 5365647. The archived webcast will be available on Schrödinger's website for approximately 90 days following the event…

    Schrödinger (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a conference call and webcast on Thursday, August 12, 2021, at 8:30 a.m. ET to discuss second quarter 2021 financial results and provide a general business update.

    The live webcast can be accessed under "News & Events" in the investors section of Schrödinger's website, https://ir.schrodinger.com/news-and-events/event-calendar. To participate in the live call, please dial (833) 727-9520 (domestic) or +1 (830) 213-7697 (international) and refer to conference ID 5365647. The archived webcast will be available on Schrödinger's website for approximately 90 days following the event.

    About Schrödinger

    Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger's multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

    Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

    View Full Article Hide Full Article
  3. Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today will host its first annual Educator's Day, which will bring together K-12 and university educators from across the globe to discuss the growing role of computational tools in the classroom. Also today, the company announced "Teaching with Schrödinger," a new initiative to develop curricula for academic institutions to teach students about chemical interactions, drug design and materials research using Schrödinger software.

    "We're counting on today's students to be tomorrow's leading scientists, so it's critically important to modernize the curriculum by incorporating hands-on work with the advanced…

    Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today will host its first annual Educator's Day, which will bring together K-12 and university educators from across the globe to discuss the growing role of computational tools in the classroom. Also today, the company announced "Teaching with Schrödinger," a new initiative to develop curricula for academic institutions to teach students about chemical interactions, drug design and materials research using Schrödinger software.

    "We're counting on today's students to be tomorrow's leading scientists, so it's critically important to modernize the curriculum by incorporating hands-on work with the advanced computational tools that drive real-world discovery programs," said Karen Akinsanya, Ph.D., executive vice president, chief biomedical scientist, head of discovery R&D at Schrödinger. "There's a significant gap in resources available for this type of hands-on learning, and we are proud to begin to fill the void by launching this new curricular initiative and training teachers to use the latest computational tools."

    Educator's Day will feature presentations from skilled instructors who have successfully incorporated computational tools into courses ranging from organic chemistry to bioinformatics to pharmaceutical science. In addition, Schrödinger scientists will host breakout sessions to brainstorm new approaches for engaging students with the material and drawing connections to real-world applications. Lessons from the event will inform the Teaching with Schrödinger curriculum.

    "Facilitating effective learning is not just an art, it's a science – and it requires continually adapting pedagogy and curricula to incorporate cutting-edge tools and techniques so that students gain the knowledge and enjoyment they need to succeed in their lifelong learning and in their careers," said Dr. Brent R. Stockwell, professor of biological science and chemistry at Columbia University and the keynote speaker at Educator's Day. Stockwell has co-founded several biopharmaceutical companies, pioneered a blended learning approach to teaching biochemistry, and recently brought virtual reality technology into his classrooms with the help of interdisciplinary colleagues across Columbia University in the Science of Learning Research Initiative, the Libraries Digital Programs, Information Technology/Emerging Technologies, and the School of Professional Studies.

    Schrödinger's Educator's Day event starts today at 11 a.m. EDT. The event is open to the public, and interested guests can register here.

    About Schrödinger

    Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger's multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

    Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

    View Full Article Hide Full Article
  4. Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on July 15, 2021, the company granted non-statutory stock options to purchase an aggregate of 32,975 shares of the company's common stock to 14 newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

    The…

    Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on July 15, 2021, the company granted non-statutory stock options to purchase an aggregate of 32,975 shares of the company's common stock to 14 newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

    The stock options have an exercise price of $67.46 per share, equal to the closing price of Schrödinger's common stock on July 15, 2021. Each stock option has a ten-year term and vests over four years, with 25 percent of the shares underlying the option vesting when the employee completes 12 months of continuous service measured from the employment start date and the balance of the shares vesting in a series of successive equal monthly installments of 1/48 of the original number of shares upon the employee's completion of each additional month of service over the 36 months following the first anniversary of the employment start date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company's 2021 Inducement Equity Incentive Plan.

    About Schrödinger

    Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger's multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

    Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

    View Full Article Hide Full Article
  5. Schrödinger (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will present at two investor conferences in July. On Tuesday, July 20, 2021, Schrödinger will provide a corporate overview at the Evercore ISI AI x Therapeutics Day. The presentation will take place virtually at 1:30 pm. ET.

    Additionally, the company will present virtually at the SVB Leerink CybeRx: Big Data, A.I. & Machine Learning in Healthcare Conference on Wednesday, July 28, 2021, at 2:00 p.m. ET.

    About Schrödinger

    Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery…

    Schrödinger (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will present at two investor conferences in July. On Tuesday, July 20, 2021, Schrödinger will provide a corporate overview at the Evercore ISI AI x Therapeutics Day. The presentation will take place virtually at 1:30 pm. ET.

    Additionally, the company will present virtually at the SVB Leerink CybeRx: Big Data, A.I. & Machine Learning in Healthcare Conference on Wednesday, July 28, 2021, at 2:00 p.m. ET.

    About Schrödinger

    Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger's multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

    Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

    View Full Article Hide Full Article
View All Schrodinger Inc. News